Cargando…

Management of dermatologic toxicities related to epidermal growth factor receptor inhibitor therapy across Europe: can we get a consensus?

To date, there are no phase III trial data that can guide healthcare professionals in managing toxicities of epidermal growth factor receptor inhibitors (EGFRIs). This exploratory survey assessed the similarities and differences in nursing management of EGFRI-related toxicities across 10 European co...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lemmens, L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2011
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223953/ https://www.ncbi.nlm.nih.gov/pubmed/22276062 http://dx.doi.org/10.3332/ecancer.2011.220

Ejemplares similares

Dermatologic Toxicities in Epidermal Growth Factor Receptor and Multikinase Inhibitors
por: Eaby-Sandy, Beth, et al.
Publicado: (2012)

Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review
por: Leporini, Christian, et al.
Publicado: (2013)

Dermatological Side Effects of Epidermal Growth Factor Receptor Inhibitors: ‘PRIDE’ Complex
por: Madke, Bhushan, et al.
Publicado: (2014)

Epidermal bulla: A dermatology complication of radial artery compression band
por: Vasu, Nandhakumar, et al.
Publicado: (2018)

The use of epidermal growth factor in dermatological practice
por: Shin, Sun Hye, et al.
Publicado: (2022)

Allopurinol-Induced Uncommon Dermatological Emergency of Toxic Epidermal Necrolysis (TEN)
por: Pabani, Umesh Kumar, et al.
Publicado: (2023)

Recent Dermatological Treatments for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Japan
por: Hsieh, Ming-Hsiu, et al.
Publicado: (2021)

Cutaneous Toxicity in Oncologic Patients Receiving Epidermal Growth Factor Receptor Inhibitors
por: POPA, CRISTINA-MARIA, et al.
Publicado: (2021)

Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors: are we actually ready?
por: Tabbò, Fabrizio, et al.
Publicado: (2020)

A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor‐Induced Skin Toxicities
por: Kim, Young Saing, et al.
Publicado: (2019)

Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology()()
por: Bagatin, Ediléia, et al.
Publicado: (2020)

Psychiatric training in perinatal mental health across Europe
por: Casanova Dias, Marisa, et al.
Publicado: (2022)

The role of epidermal sphingolipids in dermatologic diseases
por: Borodzicz, Sonia, et al.
Publicado: (2016)

Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma
por: Wernicke, A Gabriella, et al.
Publicado: (2010)

Breaking Bad News: Can We Get It Right?
por: Kurer, MA, et al.
Publicado: (2008)

Societies to genes: can we get there from here?
por: Page, Robert E
Publicado: (2021)

A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013
por: Wong, Siu-Fun, et al.
Publicado: (2020)

External financial dependence and firms’ crisis performance across Europe
por: Eppinger, Peter S., et al.
Publicado: (2021)

Do Terrorists Get the Attention They Want?: Comparing Effects of Terrorism across Europe
por: Nussio, Enzo, et al.
Publicado: (2021)

Both Wnt signaling and epidermal stem cell-derived extracellular vesicles are involved in epidermal cell growth
por: Leng, Ling, et al.
Publicado: (2020)

Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies
por: Li, Yanping, et al.
Publicado: (2022)

A compilation of research working groups on drug utilisation across Europe
por: Sabaté, Mònica, et al.
Publicado: (2014)

LHC configuration: can we get to β * =40 CM?
por: Bruce, R, et al.
Publicado: (2016)

How can we get intelligent systems close to experiments?
por: Böck, R K, et al.
Publicado: (1988)

Open Access: How can we get there from here?
por: Blume, Martin
Publicado: (2006)

AGING INTERVENTIONS GET HUMAN: CAN WE EXTEND HEALTHSPAN?
por: Kennedy, Brian
Publicado: (2019)

Preoperative mitral annulus size – Can we get it right?
por: Panicker, Varghese T., et al.
Publicado: (2021)

How Can We “Get the Lead Out” Without Chelators?
por: Mazer-Amirshahi, Maryann, et al.
Publicado: (2021)

INDIAN JOURNAL OF DERMATOLOGY GETS RE-INDEXED WITH PUBMED
por: Dhar, Sandipan
Publicado: (2010)

COVID-19 in dermatology practice: getting back on track
por: Cembrano, Kathryn Anne G., et al.
Publicado: (2020)

Consensus on the treatment of vitiligo – Brazilian Society of Dermatology()()
por: Dellatorre, Gerson, et al.
Publicado: (2020)

Palliative care competencies for geriatricians across Europe: a Delphi consensus study
por: Pautex, Sophie, et al.
Publicado: (2021)

Developing Core Outcome Sets for Vascular Conditions Across Europe, Not as Easy as It Sounds
por: Machin, Matthew, et al.
Publicado: (2022)

Wildtype epidermal growth factor receptor (Egfr) is not required for daily locomotor or masking behavior in mice
por: Roberts, Reade B, et al.
Publicado: (2006)

Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
por: Bangsgaard, Nannie, et al.
Publicado: (2012)

Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe
por: Génin, Emmanuelle, et al.
Publicado: (2011)

Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin Toxicities
por: Dsouza, Philomena Charlotte, et al.
Publicado: (2017)

LOW CHROMATE DIET IN DERMATOLOGY
por: Sharma, Ashimav Deb
Publicado: (2009)

How can we begin to measure recovery?
por: Dodge, Karen, et al.
Publicado: (2010)

Influenza: Can we cope better with the unpredictable?
por: Dos Santos, Gaël, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v0sbjvdav9uo9crgu6psmau5ab